-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the website of the Hunan Provincial Medical Insurance Bureau issued the "Notice on Price Correction and Price Restriction of Some Drugs" (hereinafter referred to as the "Notice"), and decided to make a decision on the price difference and obvious price quality of the online listing in the same listing catalog.
10 drugs, including famotidine, which do not match, have many mutual complaints, and were reported to be inflated by their real names, have their prices corrected and their prices limited to the Internet
.
Specifically, the generic names of drugs listed on the Internet for price correction and price limit in Hunan Province include Citicoline, Betahistine, Piracetam, Ligustrazine, Famotidine, Ranitidine, Troxerruc Butyl, aminophylline, dihydroprophylline, theophylline
.
It is worth mentioning that after the "Notice" was released, the Hunan Provincial Public Resource Trading Service Platform also issued a "Notice on Doing a Good Job in Correcting Some Drug Prices and Limiting Prices on the Internet" on January 20
.
For the 373 product specifications with the same medical insurance dosage form under the generic name declared on the Hunan Pharmaceutical Purchasing Platform, after review, it was found that only 33 product specifications meet the price limit rules, and the remaining 340 product specifications do not meet the regulations and require price correction.
And limit price hanging net
.
The industry believes that from the above point of view, carrying out drug price correction and price limit listing has become an effective means to solve the inflated drug prices and rectify the order of the pharmaceutical market
.
In the future, as more and more provinces and cities gain certain experience in this field, this may become a normal phenomenon
.
In fact, with the continuous promotion of centralized drug procurement organized by the state and the accelerated reshuffle of the pharmaceutical market, in recent years, drug price adjustment and withdrawal from the Internet have long become the norm
.
It is understood that before Hunan Province, the Sichuan Provincial Medicine and Equipment Recruitment and Procurement Center has just withdrawn the 186 products that concealed the lowest listing price/bidding price (Tibet price) in the country
.
The drugs withdrawn include lidocaine hydrochloride injection, ornidazole tablets, ribavirin tablets and other commonly used clinical western medicines, as well as Chinese patent medicines such as Niuhuangjiedu tablets and Banlangen granules.
.
In addition, earlier, the "Shaanxi Province Notice on the Price Adjustment of the Fourth Batch of Nationally Organized Centralized Drug Purchasing" (hereinafter referred to as the "Notice") issued by the Shaanxi Provincial Pharmaceutical Equipment Centralized Purchasing Network also showed that 60 products (hereinafter referred to as the "Notice") were selected to supply Shaanxi.
(referred to as "selected product"), the purchase price of the online purchase shall be adjusted according to the selected price; the original research drugs, reference preparations, and 205 drugs that have passed the evaluation of quality and efficacy consistency in Shaanxi Province shall be re-declared for their prices; there is no current online purchase.
For the 329 products whose price and current listing price are higher than the selected price, the listing price shall be re-declared, and the declared listing price shall not be higher than the price of the selected product in Shaanxi
.
The industry believes that as more and more regions monitor drug prices and adjust prices, it also means that a new round of price adjustments and withdrawals from the Internet will be swept across the country
.
In this context, pharmaceutical companies need to give full play to their own advantages, speed up the research and development of innovative products, have leading products with core competitiveness, make every effort to do a good job of consistency evaluation, and actively participate in the centralized procurement of drugs by the state and various provinces.
not easily eliminated
.
10 drugs, including famotidine, which do not match, have many mutual complaints, and were reported to be inflated by their real names, have their prices corrected and their prices limited to the Internet
.
Specifically, the generic names of drugs listed on the Internet for price correction and price limit in Hunan Province include Citicoline, Betahistine, Piracetam, Ligustrazine, Famotidine, Ranitidine, Troxerruc Butyl, aminophylline, dihydroprophylline, theophylline
.
It is worth mentioning that after the "Notice" was released, the Hunan Provincial Public Resource Trading Service Platform also issued a "Notice on Doing a Good Job in Correcting Some Drug Prices and Limiting Prices on the Internet" on January 20
.
For the 373 product specifications with the same medical insurance dosage form under the generic name declared on the Hunan Pharmaceutical Purchasing Platform, after review, it was found that only 33 product specifications meet the price limit rules, and the remaining 340 product specifications do not meet the regulations and require price correction.
And limit price hanging net
.
The industry believes that from the above point of view, carrying out drug price correction and price limit listing has become an effective means to solve the inflated drug prices and rectify the order of the pharmaceutical market
.
In the future, as more and more provinces and cities gain certain experience in this field, this may become a normal phenomenon
.
In fact, with the continuous promotion of centralized drug procurement organized by the state and the accelerated reshuffle of the pharmaceutical market, in recent years, drug price adjustment and withdrawal from the Internet have long become the norm
.
It is understood that before Hunan Province, the Sichuan Provincial Medicine and Equipment Recruitment and Procurement Center has just withdrawn the 186 products that concealed the lowest listing price/bidding price (Tibet price) in the country
.
The drugs withdrawn include lidocaine hydrochloride injection, ornidazole tablets, ribavirin tablets and other commonly used clinical western medicines, as well as Chinese patent medicines such as Niuhuangjiedu tablets and Banlangen granules.
.
In addition, earlier, the "Shaanxi Province Notice on the Price Adjustment of the Fourth Batch of Nationally Organized Centralized Drug Purchasing" (hereinafter referred to as the "Notice") issued by the Shaanxi Provincial Pharmaceutical Equipment Centralized Purchasing Network also showed that 60 products (hereinafter referred to as the "Notice") were selected to supply Shaanxi.
(referred to as "selected product"), the purchase price of the online purchase shall be adjusted according to the selected price; the original research drugs, reference preparations, and 205 drugs that have passed the evaluation of quality and efficacy consistency in Shaanxi Province shall be re-declared for their prices; there is no current online purchase.
For the 329 products whose price and current listing price are higher than the selected price, the listing price shall be re-declared, and the declared listing price shall not be higher than the price of the selected product in Shaanxi
.
The industry believes that as more and more regions monitor drug prices and adjust prices, it also means that a new round of price adjustments and withdrawals from the Internet will be swept across the country
.
In this context, pharmaceutical companies need to give full play to their own advantages, speed up the research and development of innovative products, have leading products with core competitiveness, make every effort to do a good job of consistency evaluation, and actively participate in the centralized procurement of drugs by the state and various provinces.
not easily eliminated
.
